Nothing Special   »   [go: up one dir, main page]

ATE493396T1 - Neue indazolcarboxamide und ihre verwendung - Google Patents

Neue indazolcarboxamide und ihre verwendung

Info

Publication number
ATE493396T1
ATE493396T1 AT05769167T AT05769167T ATE493396T1 AT E493396 T1 ATE493396 T1 AT E493396T1 AT 05769167 T AT05769167 T AT 05769167T AT 05769167 T AT05769167 T AT 05769167T AT E493396 T1 ATE493396 T1 AT E493396T1
Authority
AT
Austria
Prior art keywords
indazolcarboxamides
new
new indazolcarboxamides
Prior art date
Application number
AT05769167T
Other languages
English (en)
Inventor
Jeffrey Kerns
Christine Edwards
Original Assignee
Glaxosmithkline Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Llc filed Critical Glaxosmithkline Llc
Application granted granted Critical
Publication of ATE493396T1 publication Critical patent/ATE493396T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Obesity (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
AT05769167T 2004-06-24 2005-06-24 Neue indazolcarboxamide und ihre verwendung ATE493396T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US58265504P 2004-06-24 2004-06-24
PCT/US2005/022870 WO2006002434A2 (en) 2004-06-24 2005-06-24 Novel indazole carboxamides and their use

Publications (1)

Publication Number Publication Date
ATE493396T1 true ATE493396T1 (de) 2011-01-15

Family

ID=35782386

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05769167T ATE493396T1 (de) 2004-06-24 2005-06-24 Neue indazolcarboxamide und ihre verwendung

Country Status (21)

Country Link
US (1) US8501780B2 (de)
EP (1) EP1758578B1 (de)
JP (1) JP5017105B2 (de)
KR (1) KR20070043940A (de)
CN (1) CN101005836A (de)
AR (1) AR050253A1 (de)
AT (1) ATE493396T1 (de)
AU (1) AU2005258332A1 (de)
BR (1) BRPI0512533A (de)
CA (1) CA2571712A1 (de)
DE (1) DE602005025632D1 (de)
ES (1) ES2358579T3 (de)
IL (1) IL179747A0 (de)
MA (1) MA28727B1 (de)
MX (1) MXPA06014481A (de)
NO (1) NO20070076L (de)
PE (1) PE20060373A1 (de)
RU (1) RU2007102576A (de)
TW (1) TW200616967A (de)
WO (1) WO2006002434A2 (de)
ZA (1) ZA200609759B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0400895D0 (en) * 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
AU2006266028B2 (en) * 2005-06-30 2012-03-15 Smithkline Beecham Corporation Chemical compounds
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
US20080269291A1 (en) * 2005-11-18 2008-10-30 Kerns Jeffrey K Chemical Compounds
BRPI0707718A2 (pt) * 2006-02-10 2011-05-10 Summit Corp Plc uso de um composto
JP5019768B2 (ja) * 2006-03-23 2012-09-05 独立行政法人科学技術振興機構 新規低分子化合物およびその製造方法
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB0804592D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
GB0804591D0 (en) * 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
KR101323448B1 (ko) 2008-10-02 2013-11-27 아사히 가세이 파마 가부시키가이샤 ８위 치환 이소퀴놀린 유도체 및 이의 용도
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
WO2010120854A1 (en) * 2009-04-15 2010-10-21 Glaxosmithkline Llc Chemical compounds
JP2015214492A (ja) * 2012-09-07 2015-12-03 大日本住友製薬株式会社 ３−（４−ピペリジル）−インダゾール誘導体
PE20190657A1 (es) 2016-09-23 2019-05-08 Novartis Ag Compuestos de indazol para usar en lesiones de tendones y/o ligamentos
JOP20190053A1 (ar) 2016-09-23 2019-03-21 Novartis Ag مركبات أزا إندازول للاستخدام في إصابات الأوتار و/ أو الرباط
UY38765A (es) * 2019-06-27 2021-01-29 Biogen Ma Inc Derivados de 2h-indazol y su uso en el tratamiento de enfermedades

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775761A (en) * 1983-08-22 1988-10-04 Hoechst-Roussel Pharmaceuticals, Inc. 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
DE3342632A1 (de) 1983-11-25 1985-06-05 Merck Patent Gmbh, 6100 Darmstadt Indolderivate
US5256673A (en) * 1983-11-25 1993-10-26 Merck Patent Gesellschaft Mit Beschrankter Haftung Indole-3-yl-A-tetrahydropyridyl or piperidyl compounds
DE3882732T2 (de) 1987-02-10 1993-12-02 Abbott Lab Indol, Benzofuran, Benzothiophen enthaltende, Lipoxygenase hemmende Verbindungen.
JPH0262875A (ja) * 1988-05-23 1990-03-02 Wakunaga Pharmaceut Co Ltd 新規イソインドリン誘導体
IE903206A1 (en) 1989-09-07 1991-03-13 Abbott Lab Indole-, benzofuran-, and benzothiophene-containing¹lipoxygenase-inhibiting compounds
US5254473A (en) * 1990-03-16 1993-10-19 Jp Laboratories Solid state device for monitoring integral values of time and temperature of storage of perishables
JP2963288B2 (ja) 1992-01-14 1999-10-18 株式会社海洋バイオテクノロジー研究所 水中有害付着生物防除剤
US5330986A (en) * 1992-11-24 1994-07-19 Hoechst-Roussel Pharmaceuticals Inc. Indole-7-carboxamide derivatives
FR2701026B1 (fr) 1993-02-02 1995-03-31 Adir Nouveaux dérivés de l'indole, de l'indazole et du benzisoxazole, leur procédé de préparation et les compositions pharmaceutiques qui les contiennent.
GB9305623D0 (en) 1993-03-18 1993-05-05 Merck Sharp & Dohme Therapeutic agents
WO1994021627A1 (en) 1993-03-18 1994-09-29 Merck Sharp & Dohme Limited Indole derivatives as dopamine d4 antagonists
ZA951822B (en) * 1994-12-23 1996-09-26 Glaxo Group Ltd Chemical compounds
DE19500689A1 (de) 1995-01-12 1996-07-18 Merck Patent Gmbh Indolpiperidin-Derivate
US5780496A (en) 1995-06-07 1998-07-14 Sugen, Inc. Method and compositions for inhibition of adaptor protein/tyrosine kinase interactions
GB9610811D0 (en) 1996-05-23 1996-07-31 Pharmacia Spa Combinatorial solid phase synthesis of a library of indole derivatives
US5846982A (en) 1996-06-14 1998-12-08 Eli Lilly And Company Inhibition of serotonin reuptake
EP1077213A3 (de) 1996-06-14 2001-06-13 Eli Lilly And Company Hemmung der Serotoninwiederaufnahme
JP2001506230A (ja) 1996-08-09 2001-05-15 スミスクライン・ビーチャム・コーポレイション 新規ピペラジン含有化合物
WO1998028292A1 (en) 1996-12-23 1998-07-02 Smithkline Beecham Corporation Novel piperidine containing compounds
CA2298701A1 (en) 1997-08-06 1999-02-18 Eli Lilly And Company 2-acylaminopropanamines as tachykinin receptor antagonists
AR013669A1 (es) 1997-10-07 2001-01-10 Smithkline Beecham Corp Compuestos y metodos
DE19756036A1 (de) * 1997-12-17 1999-06-24 Merck Patent Gmbh Amid- und Harnstoffderivate
DE19807993A1 (de) 1998-02-26 1999-09-02 Bayer Ag Verwendung von ß-Carbolinderivaten zur Bekämpfung von TNF-alpha-abhängigen Krankheiten
EP1057813B1 (de) 1998-02-27 2004-04-21 Kissei Pharmaceutical Co., Ltd. Indol-derivate und medizinische zusammensetzungen die diese enthalten
US6589954B1 (en) * 1998-05-22 2003-07-08 Scios, Inc. Compounds and methods to treat cardiac failure and other disorders
WO2000000487A1 (en) 1998-06-30 2000-01-06 Eli Lilly And Company 5-ht1f agonists
BR0012450B1 (pt) 1999-06-23 2011-08-23 benzimidazóis substituìdos.
DE19928424A1 (de) 1999-06-23 2000-12-28 Aventis Pharma Gmbh Substituierte Benzimidazole
AR025111A1 (es) * 1999-08-13 2002-11-06 Janus Pharmaceuticals Inc Metodos y composiciones para tratar trastornos de ansiedad generalizada
DE19951360A1 (de) 1999-10-26 2001-05-03 Aventis Pharma Gmbh Substituierte Indole
CA2390531A1 (en) 1999-11-08 2001-05-17 Wyeth ¬(indol-3-yl)-cycloalkyl|-3-substituted azetidines for the treatment of central nervous system disorders
US6245799B1 (en) * 1999-11-08 2001-06-12 American Home Products Corp [(Indol-3-yl)-cycloalkyl]-3-substituted azetidines for the treatment of central nervous system disorders
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
WO2001068648A1 (en) 2000-03-15 2001-09-20 Aventis Pharma Deutschland Gmbh Substituted beta-carbolines with ikb-kinase inhibiting activity
EP1209158A1 (de) 2000-11-18 2002-05-29 Aventis Pharma Deutschland GmbH Substitutierte beta-Carboline
EP1134221A1 (de) 2000-03-15 2001-09-19 Aventis Pharma Deutschland GmbH Substituierte beta-Carboline als lkB-Kinasehemmer
EP1276739A2 (de) * 2000-04-24 2003-01-22 Bristol-Myers Squibb Company Heterozyklische verbindungen und deren verwendung als impdh enzym inhibitoren
NZ521978A (en) 2000-04-28 2004-10-29 Acadia Pharm Inc Compounds that affect cholinergic receptors and are particularly muscarinic agonists
EP1293206A4 (de) 2000-05-15 2005-09-21 Kissei Pharmaceutical Flüssige zubereitung auf wasserbasis
US6414013B1 (en) 2000-06-19 2002-07-02 Pharmacia & Upjohn S.P.A. Thiophene compounds, process for preparing the same, and pharmaceutical compositions containing the same background of the invention
US20050009876A1 (en) * 2000-07-31 2005-01-13 Bhagwat Shripad S. Indazole compounds, compositions thereof and methods of treatment therewith
US6897231B2 (en) * 2000-07-31 2005-05-24 Signal Pharmaceuticals, Inc. Indazole derivatives as JNK inhibitors and compositions and methods related thereto
MXPA03001420A (es) 2000-08-14 2004-01-26 Johnson & Johnson Pirazoles sustituidos.
EP1311502A1 (de) 2000-08-17 2003-05-21 Celltech R&D Limited Bizyklische heteroaromatische derivate für die behandlung von immun und inflammatorischen störungen
US6868504B1 (en) * 2000-08-31 2005-03-15 Micron Technology, Inc. Interleaved delay line for phase locked and delay locked loops
CN1642973A (zh) * 2000-09-06 2005-07-20 奥索-麦克尼尔药品公司 治疗变态反应的方法
JP4272338B2 (ja) 2000-09-22 2009-06-03 バイエル アクチェンゲゼルシャフト ピリジン誘導体
HUP0302925A3 (en) 2000-10-03 2004-10-28 Bristol Myers Squibb Co Amino-substituted tetracyclic compouds useful as anti-inflammatory agents and pharmaceutical compositions comprising same
US6869956B2 (en) * 2000-10-03 2005-03-22 Bristol-Myers Squibb Company Methods of treating inflammatory and immune diseases using inhibitors of IκB kinase (IKK)
EP1324759A4 (de) 2000-10-12 2004-05-12 Smithkline Beecham Corp Nf--g(k)b inhibitoren
AU2002211662A1 (en) 2000-10-12 2002-04-22 Smith Kline Beecham Corporation Nf-kappab inhibitors
ES2305125T3 (es) * 2000-10-26 2008-11-01 Amgen Inc. Agentes anti-inflamatorios.
JP2002193938A (ja) 2000-12-01 2002-07-10 Bayer Ag ４−アリールピリジン誘導体
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
CN1281605C (zh) 2000-12-22 2006-10-25 惠氏公司 作为5－羟色胺－6配基的杂环基－吲唑或氮杂吲唑化合物
AU2002247059B2 (en) 2001-02-01 2006-11-16 Bristol-Myers Squibb Company Method of treating inflammatory and immune diseases using inhibitors of IkappaB kinase (IKK)
DE10112151A1 (de) 2001-03-14 2002-09-19 Merck Patent Gmbh Substituierte Benzofuran-2-carbonsäureamide
WO2002094265A1 (en) 2001-05-24 2002-11-28 Leo Pharma A/S A method of modulating nf-$g(k)b activity
KR20030097897A (ko) 2001-05-24 2003-12-31 레오 파마 에이/에스 신규한 피리딜 시아노구아니딘 화합물
US20030045515A1 (en) 2001-05-24 2003-03-06 Lise Binderup Combination medicament for treatment of neoplastic diseases
MXPA03011244A (es) * 2001-06-07 2004-02-27 Hoffmann La Roche Nuevos derivados de indol con afinidad por el receptor 5-ht6.
US6638679B2 (en) 2001-07-12 2003-10-28 Kodak Polychrome Graphics, Llc Photosensitive compositions having mixtures of alkoxy and non-alkoxy diazonium salt containing compounds
SE0102617D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
SE0102616D0 (sv) 2001-07-25 2001-07-25 Astrazeneca Ab Novel compounds
US20030127204A1 (en) 2001-09-06 2003-07-10 Varnell Daniel F. Amphoteric polymer resins that increase the rate of sizing development
DE60220422T2 (de) 2001-09-19 2008-02-07 Pharmacia Corp. Substituierte pyrazol-verbindungen zur behandlung von entzündungen
AR037090A1 (es) 2001-09-19 2004-10-20 Pharmacia Corp Compuestos pirazolilo sustituidos para el tratamiento de inflamaciones
WO2003035625A1 (en) 2001-09-19 2003-05-01 Pharmacia Corporation Substituted indazole compounds for the treatment of inflammation
BR0212661A (pt) 2001-09-19 2004-08-24 Pharmacia Corp Compostos de pirazolil benzenossulfamida substituìdos para o tratamento de inflamação
CA2464924A1 (en) 2001-10-30 2003-05-08 Pharmacia Corporation Heteroaromatic carboxamide derivatives for the treatment of inflammation
NZ534333A (en) 2002-02-14 2006-05-26 Glaxo Group Ltd Pharmaceutical composition comprising N-[(1-n-butyl-4-piperidinyl) methyl]-3,4-dihydro-2H-[1, 3]oxazino[3, 2-a]indole-10-carboxamide or salt, and process for preparing thereof comprising dry granulation
ATE370145T1 (de) 2002-04-03 2007-09-15 Bristol Myers Squibb Co Tricyclische verbindungen auf thiophengrundlage und pharmazeutische zusammensetzungen, die diese enthalten
JP2005526831A (ja) 2002-04-09 2005-09-08 アステックス テクノロジー リミテッド 医薬化合物
AR039280A1 (es) * 2002-04-11 2005-02-16 Smithkline Beecham Corp Compuesto de aminotiofeno y su uso para preparar una composicion farmaceutica
AU2003220483A1 (en) 2002-05-09 2003-11-11 Pharmacia Corporation Substituted pyrazolyl compounds for the treatment of inflammation
US20040034084A1 (en) * 2002-05-24 2004-02-19 Celgene Corporation Methods for using JNK inhibitors for treating or preventing disease-related wasting
WO2003101987A1 (en) 2002-05-30 2003-12-11 Neurosearch A/S 3-substituted quinuclidines and their use
US7375131B2 (en) 2002-06-06 2008-05-20 Smithklinebeecham Corp. NF-κB inhibitors
ATE415966T1 (de) 2002-06-06 2008-12-15 Boehringer Ingelheim Pharma Substituierte 3-amino-thieno(2,3-b)pyridine-2- amide und herstellungsverfahren sowie deren verwendung
DE10237722A1 (de) 2002-08-17 2004-08-19 Aventis Pharma Deutschland Gmbh Indol- oder Benzimidazolderivate zur Modulation der IKappaB-Kinase
BR0313923A (pt) 2002-08-29 2005-07-12 Boehringer Ingelheim Pharma Derivados de 3-(sulfonamidoetil)-indol para uso como miméticos de glicocorticóide no tratamento de doenças inflamatórias, alérgicas e proliferativas
US6919334B2 (en) 2002-09-12 2005-07-19 Wyeth Antidepressant azaheterocyclymethyl derivatives of 4,5-dihydroimidazo[1,4,5-de][1,4]benzoxazine
US6911445B2 (en) 2002-09-12 2005-06-28 Wyeth Antidepressant cycloalkylamine derivatives of heterocycle-fused benzodioxans
US7135479B2 (en) 2002-09-12 2006-11-14 Wyeth Antidepressant azaheterocyclylmethyl derivatives of heterocycle-fused benzodioxans
PT1567112E (pt) 2002-11-22 2009-01-08 Smithkline Beecham Corp Novos compostos químicos
ATE399768T1 (de) * 2002-12-02 2008-07-15 Hoffmann La Roche Indazolderivate und ihre verwendung als crf antagonisten
WO2004053087A2 (en) * 2002-12-06 2004-06-24 Smithkline Beecham Corporation Nf-κb inhibitors
DE10259244A1 (de) 2002-12-17 2004-07-01 Merck Patent Gmbh N-(Indolethyl-)cycloamin-Verbindungen
WO2004075846A2 (en) 2003-02-25 2004-09-10 Bristol-Myers Squibb Company Pyrazolopurine-based tricyclic compounds and pharmaceutical compositions comprising same
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
CA2534127A1 (en) 2003-07-31 2005-02-10 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzothiophene compounds and uses thereof
ATE359283T1 (de) 2003-10-14 2007-05-15 Pharmacia Corp Substituierte pyrazinonverbindungen zur behandlung von entzündungen
JP2007511618A (ja) * 2003-11-19 2007-05-10 シグナル ファーマシューティカルズ，エルエルシー インダゾール化合物およびタンパク質キナーゼ阻害剤としてのその使用方法
WO2005061519A1 (en) * 2003-12-19 2005-07-07 Takeda San Diego, Inc. Kinase inhibitors
GB0400895D0 (en) 2004-01-15 2004-02-18 Smithkline Beecham Corp Chemical compounds
DE102004012069A1 (de) * 2004-03-12 2005-09-29 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue aryl-haltige 5-Acylindolinone, deren Herstellung und deren Verwendung als Arzneimittel
PE20060373A1 (es) 2004-06-24 2006-04-29 Smithkline Beecham Corp Derivados 3-piperidinil-7-carboxamida-indazol como inhibidores de la actividad cinasa de ikk2
PE20060748A1 (es) * 2004-09-21 2006-10-01 Smithkline Beecham Corp Derivados de indolcarboxamida como inhibidores de quinasa ikk2
KR20080009200A (ko) 2005-04-06 2008-01-25 아스트라제네카 아베 치환된 헤테로사이클 및 이것의 ｃｈｋ1, ｐｄｋ1 및ｐａｋ 억제제로서의 용도
US7375219B2 (en) 2005-04-13 2008-05-20 Neuraxon, Inc. Substituted indole compounds having NOS inhibitory activity
US8063071B2 (en) * 2007-10-31 2011-11-22 GlaxoSmithKline, LLC Chemical compounds
EP1916245B1 (de) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indolderivat mit pgd2-rezeptor-antagonistischer wirkung
EP1940394A4 (de) * 2005-10-25 2009-07-08 Smithkline Beecham Corp Chemische verbindungen
US20080242685A1 (en) * 2005-10-25 2008-10-02 Smithkline Beecham Corporation Chemical Compounds
US20080269291A1 (en) * 2005-11-18 2008-10-30 Kerns Jeffrey K Chemical Compounds
JP2009519968A (ja) * 2005-12-16 2009-05-21 スミスクライン・ビーチャム・コーポレイション 化学物質
US8008481B2 (en) * 2006-03-31 2011-08-30 Ericsson Anna M Indazole compounds
WO2008034860A1 (en) * 2006-09-22 2008-03-27 Glaxo Group Limited Pyrrolo[2, 3-b]pyridin-4-yl-benzenesulfonamide compounds as ikk2 inhibitors
PE20081889A1 (es) * 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
GB0804592D0 (en) 2008-03-12 2008-04-16 Glaxo Group Ltd Novel compounds
WO2010102968A1 (en) 2009-03-10 2010-09-16 Glaxo Group Limited Indole derivatives as ikk2 inhibitors
US20120058984A1 (en) 2009-03-17 2012-03-08 Catherine Mary Alder Pyrimidine derivatives used as itk inhibitors

Also Published As

Publication number Publication date
EP1758578A4 (de) 2009-05-27
RU2007102576A (ru) 2008-07-27
WO2006002434A2 (en) 2006-01-05
WO2006002434A3 (en) 2006-06-15
CA2571712A1 (en) 2006-01-05
EP1758578A2 (de) 2007-03-07
MA28727B1 (fr) 2007-07-02
PE20060373A1 (es) 2006-04-29
DE602005025632D1 (de) 2011-02-10
BRPI0512533A (pt) 2008-03-25
MXPA06014481A (es) 2007-03-01
AU2005258332A1 (en) 2006-01-05
AR050253A1 (es) 2006-10-11
EP1758578B1 (de) 2010-12-29
NO20070076L (no) 2007-02-26
TW200616967A (en) 2006-06-01
US8501780B2 (en) 2013-08-06
JP2008504296A (ja) 2008-02-14
JP5017105B2 (ja) 2012-09-05
IL179747A0 (en) 2007-05-15
ES2358579T3 (es) 2011-05-11
ZA200609759B (en) 2007-10-31
KR20070043940A (ko) 2007-04-26
US20070281933A1 (en) 2007-12-06
CN101005836A (zh) 2007-07-25

Similar Documents

Publication Publication Date Title
ATE454384T1 (de) Neue pyridazinverbindung und ihre verwendung
ATE428710T1 (de) Substituierte phenylaminothiazole und ihre verwendung
DE602005003186D1 (de) Fluorkopolymer und dessen Verwendung
ATE409700T1 (de) Cannabinoid rezeptor-liganden und ihre verwendung
ATE520681T1 (de) N-thioanthranilamidverbindungen und ihre verwendung als pestizide
ATE440093T1 (de) 1-alkinyl-2-aryloxyalkylamide und ihre verwendung als fungizide
ATE391718T1 (de) Phenylacetamide und ihre verwendung als glukokinase-modulatoren
ATE493396T1 (de) Neue indazolcarboxamide und ihre verwendung
ATE531712T1 (de) Substituierte aryloxazole und ihre verwendung
ATE432975T1 (de) Flüssigwaschmittel und ihre verwendung
DE602006016189D1 (de) Pigmentdispergatoren und ihre Verwendung
ATE479437T1 (de) Benzoä4,5üthienoä2,3-düpyrimidin-4-one und ihre therapeutische verwendung
ATE465628T1 (de) Neue vip3-toxine und ihre verwendung
DE602006009296D1 (de) Oligopeptide und ihre verwendung
DE602004010426D1 (de) Mikrobizide zusammensetzungen und ihre verwendung
DE602005021959D1 (de) Substituierte diazaspiroä4.5üdecanderivate und der
ATE384054T1 (de) Substituierte benzoxazinones und ihre verwendung
ATE387440T1 (de) Neue 4-benzylidenpiperidinderivate
ATE511507T1 (de) Piperidinylcarbonylpyrrolidine und deren verwendung als melanocortinagonisten
DE602005023145D1 (de) Neue androgene
DE502005002170D1 (de) Amphiphile polymerzusammensetzungen und ihre verwendung
ATE425167T1 (de) Neue pyridothienopyrimidinderivate
ATE531259T1 (de) 2-alkyl-cycloalk(en)yl-carboxamide und ihre verwendung als fungizide
DE502004006994D1 (de) Hitzebeständige Superlegierung und ihre Verwendung
DE602006013980D1 (de) Carboxamidverbindung und ihre verwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties